Nanoparticles traveling through the nasal passage to the brain.

Nose-to-Brain Drug Delivery: Revolutionizing Treatment with Nanotechnology

Jordan Keane in Health & Wellness October 2026 • 4 min read.

"Explore how nanoparticles are bypassing the blood-brain barrier to deliver drugs directly to the brain via nasal administration, offering new hope for neurological disorders."

The pharmaceutical industry is increasingly focused on addressing unmet medical needs, leading to the development of innovative drugs with significant therapeutic impact. While advancements have been made in treating conditions like age-related macular degeneration and certain cancers, neurological disorders such as brain tumors, Alzheimer's disease, and Parkinson's disease remain challenging due to the difficulty of delivering drugs effectively to the brain.

A major hurdle in treating brain disorders is the blood-brain barrier (BBB), a protective mechanism that restricts the passage of most drugs from the bloodstream into the brain. This barrier prevents many potentially therapeutic compounds from reaching their targets in the brain, limiting treatment options for neurological conditions.

To overcome the BBB, researchers are exploring alternative drug delivery methods, with intranasal administration emerging as a promising non-invasive approach. This method allows drugs to bypass the BBB and directly target the brain, offering new possibilities for treating neurological disorders. This article will delve into the innovative use of nanoparticles for intranasal drug delivery, focusing on their ability to enhance drug transport and therapeutic efficacy in the brain.

AI Search Multiple angles on this topic

Stats & Impact

Nanoparticles and Nose-to-Brain Delivery

Nanoparticle-based systems have made progress in strategies for helping therapeutic agents reach the central nervous system, drawing on properties associated with their nanoscale and material composition sciencedirect.com. A 2023 study notes that nanoparticles can travel by the nose-to-brain route, but quantitative information about their spatiotemporal dynamics and the factors regulating transport remains limited. That study surveyed metal oxide and hydroxide nanoparticles as MRI contrasts for tracking; its snippet reports that only nanoparticles containing divalent transition metals were capable of nose-to-brain transport link.springer.com.

History

The Nasal Route as a Brain-Delivery Strategy

The nose-to-brain approach has emerged as a strategy to address challenges in conventional drug administration for central nervous system disorders. The nasal route's anatomical advantages can enable direct transport from the nasal cavity to the brain, thereby circumventing the blood–brain barrier mdpi.com. A review of solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) discusses methods to enhance their delivery efficacy and reports advances in clinical trials involving these carriers pmc.ncbi.nlm.nih.gov.

Nanoparticles: A Key to Bypassing the Blood-Brain Barrier

Nanoparticles traveling through the nasal passage to the brain.

Nanoparticles, such as liposomes and polymeric micelles, have emerged as versatile drug carriers, capable of encapsulating drugs and targeting specific tissues. These nanoparticles can be modified to enhance their stability, prolong their circulation in the bloodstream, and improve their ability to cross biological barriers like the BBB. Their unique properties make them ideal candidates for intranasal drug delivery to the brain.

One promising type of nanoparticle for brain drug delivery is the MPEG-PCL micelle. These micelles are composed of methoxy polyethylene glycol (MPEG) and polycaprolactone (PCL), which are biocompatible and biodegradable polymers. They self-assemble into spherical structures with a hydrophobic core and a hydrophilic shell, allowing them to encapsulate hydrophobic drugs and protect them from degradation.

Here are key benefits of MPEG-PCL micelles for intranasal drug delivery:

Enhanced Drug Encapsulation: They efficiently encapsulate drugs for targeted delivery.
Improved Stability: They protect drugs from degradation, ensuring they reach their target.
Biocompatibility: They are made from biocompatible materials, minimizing toxicity.
Tunable Size: The size of micelles can be adjusted to optimize drug delivery.

AI Search Multiple angles on this topic

Latest Research

Recent Reviews of Delivery Technologies

Recent reviews survey nose-to-brain delivery advances spanning carrier design and evaluation methods pmc.ncbi.nlm.nih.gov. A June 2026 review emphasizes nanotechnology-based delivery techniques and describes their potential to address challenges in the field sciencedirect.com. Another review focuses on drug-loaded polymeric nanomicelles delivered through the nasal route, covering micelle types, preparation and characterization methods, and reported in vitro and in vivo findings for brain diseases .

Counterpoints

Unresolved Mechanisms and Evidence

The interaction mechanisms between nanoparticle drug-delivery systems and the nose-to-brain pathway remain incompletely explored, according to a 2024 review sciencedirect.com. A 2022 meta-analysis-related source lists a formulation and in vitro comparison study of lipid-based and polymeric-based nanoparticles using a model drug for Alzheimer’s disease ncbi.nlm.nih.gov. Another review describes polymer, lipid, and inorganic nanoparticles, along with drug nanocrystals, and addresses both positive perspectives and challenges of intranasal brain delivery .

To further enhance the ability of nanoparticles to cross the nasal mucosa and target brain cells, researchers have modified their surface with cell-penetrating peptides (CPPs). These peptides, such as the Tat peptide derived from the HIV-1 virus, can facilitate the transport of nanoparticles across cell membranes and into the brain. The combination of MPEG-PCL micelles and CPPs offers a powerful strategy for targeted drug delivery to the brain.

The Future of Brain Disorder Treatment

The use of nanoparticles for intranasal drug delivery represents a significant advancement in the treatment of neurological disorders. By bypassing the blood-brain barrier and delivering drugs directly to the brain, these innovative approaches offer new hope for patients with conditions that were previously difficult to treat.

While challenges remain, ongoing research is focused on optimizing nanoparticle design, improving drug encapsulation and release, and enhancing targeting strategies. As these technologies continue to evolve, they hold the potential to revolutionize the treatment of brain tumors, Alzheimer's disease, Parkinson's disease, and other debilitating neurological conditions.

With further development and clinical validation, intranasal nanoparticle drug delivery could become a mainstream approach for treating a wide range of brain disorders, offering improved outcomes and a better quality of life for patients and their families. The future of brain disorder treatment is bright, with nanotechnology leading the way.

Rat tumor results in absolute terms

14.4 daysUntreated rats survived a mean of 18.2 days; the mean was 32.6 days with intranasal CPT-loaded MPEG-PCL-Tat, a difference of 14.4 days.^[1]
4.5 times smallerAfter two weeks of treatment, tumors in the CPT-loaded MPEG-PCL-Tat group were about 4.5 times smaller than in untreated rats; after one week, the groups had similar tumor sizes.^[1]

What the rat findings suggest

In this rat tumor model, the longer mean survival and later difference in tumor size point in the same direction: the Tat-modified formulation was associated with slower tumor progression and longer survival than no treatment. These results do not establish that the formulation would have the same effects in people.^[1]

Comparisons across formulations are less conclusive than the individual results may suggest: the review reports little statistical significance between nanosystem groups, and the apparent advantage of polymeric micelles disappeared when compared with intranasal drug solutions.^[2]

What remains unresolved about nasal transport

How much of the observed delivery follows the proposed olfactory and trigeminal routes, and how much moves through perineural or perivascular spaces, remains uncertain because the precise mechanisms are not fully understood.^{[1] [3]}

Sources

Intranasal Delivery of Camptothecin-Loaded Tat-Modified Nanomicells for Treatment of Intracranial Brain Tumors (pmc.ncbi.nlm.nih.gov)
Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies. (pubmed.ncbi.nlm.nih.gov)
Perivascular and Perineural Pathways Involved in Brain Delivery and Distribution of Drugs after Intranasal Administration (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

What is the blood-brain barrier, and why is it a challenge in treating brain disorders?

The blood-brain barrier (BBB) is a protective mechanism that prevents most drugs from entering the brain from the bloodstream. This barrier is a significant hurdle in treating brain disorders because it limits the effectiveness of many potential treatments. The BBB’s role is to shield the brain from harmful substances, but it also blocks beneficial drugs.

What is intranasal administration, and why is it being explored for brain disorder treatment?

Intranasal administration refers to delivering drugs through the nose. This method is being explored as a way to bypass the blood-brain barrier (BBB) and deliver drugs directly to the brain. This direct route offers a promising way to treat neurological disorders like brain tumors and Alzheimer's disease, which are often difficult to treat due to the BBB.

What are nanoparticles, and how are they used in brain disorder treatment?

Nanoparticles are tiny structures, such as liposomes and polymeric micelles, used to carry drugs. In the context of brain disorder treatment, they are engineered to bypass the blood-brain barrier (BBB) when administered intranasally. The use of MPEG-PCL micelles are biocompatible and biodegradable polymers which can encapsulate drugs to protect them from degradation, and their size can be adjusted to optimize drug delivery, enhancing the therapeutic effect in the brain.

What are MPEG-PCL micelles, and what are their benefits in drug delivery?

MPEG-PCL micelles are a type of nanoparticle composed of methoxy polyethylene glycol (MPEG) and polycaprolactone (PCL). These materials are biocompatible and biodegradable. They self-assemble into structures that can encapsulate hydrophobic drugs, protecting them and allowing for targeted delivery to the brain via intranasal administration. The benefits include enhanced drug encapsulation, improved stability, biocompatibility, and tunable size for optimized drug delivery.

How do cell-penetrating peptides improve drug delivery to the brain?

Cell-penetrating peptides (CPPs), such as the Tat peptide, are used to modify the surface of nanoparticles. This modification enhances the ability of the nanoparticles to cross the nasal mucosa and enter brain cells. When combined with MPEG-PCL micelles, CPPs provide a powerful way to deliver drugs directly to the brain, enhancing treatment options for neurological disorders by improving drug transport and therapeutic efficacy.